Cargando…
Cervical Cancer Screening in Partly HPV Vaccinated Cohorts – A Cost-Effectiveness Analysis
BACKGROUND: Vaccination against the oncogenic human papillomavirus (HPV) types 16 and 18 will reduce the prevalence of these types, thereby also reducing cervical cancer risk in unvaccinated women. This (measurable) herd effect will be limited at first, but is expected to increase over time. At a ce...
Autores principales: | Naber, Steffie K., Matthijsse, Suzette M., Rozemeijer, Kirsten, Penning, Corine, de Kok, Inge M. C. M., van Ballegooijen, Marjolein |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4732771/ https://www.ncbi.nlm.nih.gov/pubmed/26824771 http://dx.doi.org/10.1371/journal.pone.0145548 |
Ejemplares similares
-
Comparing SurePath, ThinPrep, and conventional cytology as primary test method: SurePath is associated with increased CIN II(+) detection rates
por: Rozemeijer, Kirsten, et al.
Publicado: (2015) -
Cervical cancer incidence after normal cytological sample in routine screening using SurePath, ThinPrep, and conventional cytology: population based study
por: Rozemeijer, Kirsten, et al.
Publicado: (2017) -
The potential harms of primary human papillomavirus screening in over-screened women: a microsimulation study
por: Naber, Steffie K., et al.
Publicado: (2016) -
The health impact of human papillomavirus vaccination in the situation of primary human papillomavirus screening: A mathematical modeling study
por: Matthijsse, Suzette M., et al.
Publicado: (2018) -
Cost‐effectiveness of HPV‐based cervical screening based on first year results in the Netherlands: a modelling study
por: Jansen, EEL, et al.
Publicado: (2020)